Strategies to increase cell therapy manufacturing capabilities

Simon Ng — Mon, 28 Feb 2022 17:56:22 +0000

Shannon Eaker, PhD, Cytiva, Marlborough, MA, describes important considerations when aiming to expand the capabilities of cell therapy manufacturers, including the need to increase recruitment and training of highly skilled workers as well as retaining existing workers. Dr Eaker additionally highlights constraints in the supply chain, and factoring in the scalability of a product in its design. The advent of automation and digitization in the form of electronic batch records will also aim to address the aforementioned issues by streamlining the manufacturing process. This interview took place at Advanced Therapies Week 2022.

Digitization in the advanced therapy sector

Simon Ng — Mon, 28 Feb 2022 17:56:21 +0000

Shannon Eaker, PhD, Cytiva, Marlborough, MA, provides an overview of the significance of digitization in cell and gene therapy (CGT) manufacturing. Scaling up manufacturing remains a major barrier and digitization may be a solution to the issue. Whilst digitized standard operating procedures (SOPs) and batch records can streamline the manufacturing process, the low adoption rate due to the need for increased staff training requires to be addressed, especially when other stakeholders including regulatory authorities will digitize their records. The use of artificial intelligence (AI) can additionally enable efficient data collection and mining, which will be of particular use in the autologous setting. This interview took place at Advanced Therapies Week 2022.

Shannon Eaker – VJRegenMed

Strategies to increase cell therapy manufacturing capabilities

Digitization in the advanced therapy sector